← Olin overview

Olin vs BASF: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Olin Corporation (OLN)

Q3 2026
▲2▼2

Olin's Huntsman merger advances amid weak demand and a Q2 loss

  • Huntsman merger clears key hurdles Olin's all-stock merger with Huntsman won shareholder approval and passed U.S. antitrust review. The deal targets $300–400 million in cost savings and could add $8–11 per share, though integration risks remain.

    This is the biggest new corporate event that could reshape Olin and lift its value.

  • Weak chemicals demand causes surprise Q2 loss Soft demand for chemicals led to an unexpected second-quarter loss, sending the stock down 16% in one day. The company also gave weak third-quarter profit guidance of $160–200 million.

    This was the main negative shock that drove the stock lower during the period.

  • Epoxy and Winchester sales lift profit Strong sales in Epoxy and Winchester businesses helped adjusted EBITDA rise 8.6% to $191.3 million. A tightening chlor-alkali market could also benefit Olin over the long term.

    These bright spots show parts of the business are performing well despite overall weakness.

  • Analyst downgrade and plant disruption Citi cut its price target to $17, pointing to broad weakness in the chemicals sector. A disruption at Olin's Freeport plant added to operational concerns.

    These events reinforced negative sentiment and highlighted ongoing challenges.

August 2026
▲2▼2

Olin's Huntsman merger advances, but weak chemicals demand and losses weigh

  • Weak Q2 results and soft Q3 guidance Olin posted a wider second-quarter loss of $13.3 million as sales slipped 0.9% to $1.74 billion, and guided third-quarter EBITDA to $160–200 million, including a roughly $20 million hit from a Freeport plant disruption. Weak profits and guidance pressure the stock.

    This is the core earnings reality that sets the baseline for OLN's price this period.

  • Huntsman merger clears key hurdles Shareholders of both companies approved the all-stock merger on August 25, and the U.S. antitrust waiting period expired in September. The deal would create a larger chemicals platform with $300 million in planned cost savings, a major potential boost for Olin.

    The merger is the biggest company-specific catalyst driving OLN's outlook and valuation.

  • Epoxy and Winchester strength offset chlor alkali weakness Epoxy sales jumped 27.4% and Winchester ammunition sales rose 11.8%, lifting adjusted EBITDA 8.6% to $191.3 million and beating revenue expectations. These growing businesses are helping cushion the decline in the larger chlor alkali and vinyls segment.

    It shows which parts of Olin are actually growing and supporting profits despite overall weakness.

  • Citi cuts price target on weak chemical demand Citi kept a Neutral/High Risk rating on Olin and lowered its price target to $17 from $19, citing weak demand that is limiting gains from higher oil and feedstock costs. It also cut targets across many North American chemical peers, signaling broad sector pressure.

    This is the latest analyst view showing demand headwinds that could keep OLN's stock under pressure.

Latest
▲2▼2

Olin's Huntsman merger advances, but weak chemicals demand and losses weigh

  • Weak Q2 results and soft Q3 guidance Olin posted a wider second-quarter loss of $13.3 million as sales slipped 0.9% to $1.74 billion, and guided third-quarter EBITDA to $160–200 million, including a roughly $20 million hit from a Freeport plant disruption. Weak profits and guidance pressure the stock.

    This is the core earnings reality that sets the baseline for OLN's price this period.

  • Huntsman merger clears key hurdles Shareholders of both companies approved the all-stock merger on August 25, and the U.S. antitrust waiting period expired in September. The deal would create a larger chemicals platform with $300 million in planned cost savings, a major potential boost for Olin.

    The merger is the biggest company-specific catalyst driving OLN's outlook and valuation.

  • Epoxy and Winchester strength offset chlor alkali weakness Epoxy sales jumped 27.4% and Winchester ammunition sales rose 11.8%, lifting adjusted EBITDA 8.6% to $191.3 million and beating revenue expectations. These growing businesses are helping cushion the decline in the larger chlor alkali and vinyls segment.

    It shows which parts of Olin are actually growing and supporting profits despite overall weakness.

  • Citi cuts price target on weak chemical demand Citi kept a Neutral/High Risk rating on Olin and lowered its price target to $17 from $19, citing weak demand that is limiting gains from higher oil and feedstock costs. It also cut targets across many North American chemical peers, signaling broad sector pressure.

    This is the latest analyst view showing demand headwinds that could keep OLN's stock under pressure.

July 2026
▲2▼1

Olin's merger advances, but weak chemicals demand and a surprise loss weigh on the stock

  • Olin-Huntsman merger approved by shareholders Shareholders overwhelmingly approved the all-stock merger with Huntsman, creating a $12.5 billion chemicals company. The deal promises over $400 million in cost savings, which could boost future profits and support the stock. It is expected to close in the first half of 2027, pending regulatory approval.

    This is the latest major step in the merger and directly affects OLN's future value.

  • Surprise Q2 loss and 16% stock drop Olin reported a surprise loss of $0.12 per share, missing expectations for a profit, and revenue fell short. The stock dropped about 16% in one day. Weak chlor alkali sales and merger-related costs drove the loss, showing the company's core business is struggling.

    This is a new negative event that directly caused a sharp price decline and reflects fundamental weakness.

  • Chlor-alkali market tightening could lift Olin Hotchkis & Wiley sees North American chlor-alkali supply and demand tightening over the next five-plus years, which could raise prices and volumes. As the region's swing producer, Olin could benefit more than peers. This long-term trend offers a potential recovery path.

    This is a new analyst view on a key market driver that could improve Olin's future earnings.

  • Merger synergies valued, but integration costs and risks remain UBS estimates the merger's cost savings could add $8–$11 per share in value, mainly from procurement, operations, and overhead cuts. However, the deal also brings $10.6 million in acquisition costs and execution risk, and it does not expand into new markets, so the benefit depends on successful integration.

    This explains the financial rationale and potential value of the merger, a key driver for OLN.

▲2▼1

Olin's merger advances, but weak chemicals demand and a surprise loss weigh on the stock

  • Olin-Huntsman merger approved by shareholders Shareholders overwhelmingly approved the all-stock merger with Huntsman, creating a $12.5 billion chemicals company. The deal promises over $400 million in cost savings, which could boost future profits and support the stock. It is expected to close in the first half of 2027, pending regulatory approval.

    This is the latest major step in the merger and directly affects OLN's future value.

  • Surprise Q2 loss and 16% stock drop Olin reported a surprise loss of $0.12 per share, missing expectations for a profit, and revenue fell short. The stock dropped about 16% in one day. Weak chlor alkali sales and merger-related costs drove the loss, showing the company's core business is struggling.

    This is a new negative event that directly caused a sharp price decline and reflects fundamental weakness.

  • Chlor-alkali market tightening could lift Olin Hotchkis & Wiley sees North American chlor-alkali supply and demand tightening over the next five-plus years, which could raise prices and volumes. As the region's swing producer, Olin could benefit more than peers. This long-term trend offers a potential recovery path.

    This is a new analyst view on a key market driver that could improve Olin's future earnings.

  • Merger synergies valued, but integration costs and risks remain UBS estimates the merger's cost savings could add $8–$11 per share in value, mainly from procurement, operations, and overhead cuts. However, the deal also brings $10.6 million in acquisition costs and execution risk, and it does not expand into new markets, so the benefit depends on successful integration.

    This explains the financial rationale and potential value of the merger, a key driver for OLN.

BASF SE (BAS.XETRA)

Q3 2026
▲3▼1

BASF's coatings sale, buyback, and growth bets drive Q3

  • Coatings sale and buyback BASF completed the €7.7bn sale of its coatings business to Carlyle, boosting profit and funding a €1bn share buyback. This returns cash to shareholders and sharpens focus on core chemicals.

    Major portfolio move that directly lifted profit and shareholder returns.

  • Strong earnings and pricing power Q2 net income surged to €4.14bn, and price hikes for MDI and TDI (key chemicals) lifted margins. This shows BASF can pass on costs and benefit from tight supply.

    Earnings surge and pricing power are core drivers of investor sentiment.

  • Growth investments and potential Evonik deal New products, partnerships, capacity expansion, and AI/medical-plastics investment support future growth. A possible renewed Evonik bid could add ~20% to EPS and cash flow, though integration risks remain.

    Growth initiatives and M&A potential are forward-looking positives.

  • Regulatory and supply risks The EU emissions overhaul could raise costs, and record-low Rhine water threatens production and supply, as BASF sources ~40% of raw materials via the river. These are real headwinds.

    Environmental and logistical risks could pressure operations and costs.

September 2026
▲4

BASF pushes growth via new products, partnerships, and a possible Evonik bid

  • New product launches and partnerships expand future revenue BASF started global registration of a new herbicide, launched a low-emission catalyst and lower-carbon paper coatings, and partnered in personal care. These moves broaden BASF's product range and open new sales channels, supporting long-term revenue growth and a higher stock price.

    These are new product and partnership announcements that can drive future sales and profits, directly answering what is moving the stock.

  • Plant modernization and technology adoption boost supply and demand BASF increased acid chlorides capacity by 30% at Ludwigshafen and saw its Durasorb LNG technology adopted across Cheniere's Corpus Christi facility. Higher capacity and wider technology use can lift sales volumes and licensing revenue, pushing the stock up.

    These events show concrete operational expansions that can increase output and revenue, key drivers for the stock.

  • Possible new Evonik takeover bid could boost earnings A report says BASF may make a new offer for Evonik after an earlier bid was rejected. Analysts estimate the deal could add about 20% to earnings per share and free cash flow through 2030, though return on investment would fall and execution risks remain.

    This is a new development on the Evonik takeover that could materially affect BASF's earnings and stock price.

  • Patent lawsuit against Apple could bring damages or royalties BASF's subsidiary Trinamix sued Apple for patent infringement over facial recognition technology used in iPhones and iPads. A successful outcome could mean damages or licensing fees, adding to BASF's profits and supporting the stock.

    This is a new legal action that could result in a financial gain for BASF, affecting its stock price.

Latest
▲4

BASF pushes growth via new products, partnerships, and a possible Evonik bid

  • New product launches and partnerships expand future revenue BASF started global registration of a new herbicide, launched a low-emission catalyst and lower-carbon paper coatings, and partnered in personal care. These moves broaden BASF's product range and open new sales channels, supporting long-term revenue growth and a higher stock price.

    These are new product and partnership announcements that can drive future sales and profits, directly answering what is moving the stock.

  • Plant modernization and technology adoption boost supply and demand BASF increased acid chlorides capacity by 30% at Ludwigshafen and saw its Durasorb LNG technology adopted across Cheniere's Corpus Christi facility. Higher capacity and wider technology use can lift sales volumes and licensing revenue, pushing the stock up.

    These events show concrete operational expansions that can increase output and revenue, key drivers for the stock.

  • Possible new Evonik takeover bid could boost earnings A report says BASF may make a new offer for Evonik after an earlier bid was rejected. Analysts estimate the deal could add about 20% to earnings per share and free cash flow through 2030, though return on investment would fall and execution risks remain.

    This is a new development on the Evonik takeover that could materially affect BASF's earnings and stock price.

  • Patent lawsuit against Apple could bring damages or royalties BASF's subsidiary Trinamix sued Apple for patent infringement over facial recognition technology used in iPhones and iPads. A successful outcome could mean damages or licensing fees, adding to BASF's profits and supporting the stock.

    This is a new legal action that could result in a financial gain for BASF, affecting its stock price.

August 2026
▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

July 2026
▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.

▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.